drugset / Trial / NCT06666179
Safety and Immunogenicity Study of SCB-1019T in Children
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This phase 1 study in Australia will evaluate the safety, reactogenicity and immunogenicity of the Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T) in children 2-\<6 years of age.
Timeline
- Start
- 2025-10
- Primary completion
- 2026-06
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCB-1019T | Vaccine | — | — |